Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00899197 · ClinicalTrials.gov registry record
Tamoxifen Resistance in Women With Stage I, Stage II, Stage IIIA, or Stage IIIB Breast Cancer
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- 2
- Enrollment target
NCT00899197 is a clinical trial that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 2 participants.
The verdict
NCT00899197 was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
RATIONALE: Studying samples of blood from patients with breast cancer in the laboratory may help doctors identify and learn more about biomarkers related to tamoxifen resistance. PURPOSE: This laboratory study is looking at tamoxifen resistance in women with stage I, stage II, stage IIIA, or stage IIIB breast cancer.
Interventions
- GENETIC gene expression analysis
- GENETIC protein expression analysis
- OTHER laboratory biomarker analysis
- OTHER immunoenzyme technique
- DRUG tamoxifen citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2007-05 |
| Est. Completion | 2012-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00899197
The ClinicalTrials.gov registry entry for NCT00899197 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which gene expression analysis is the first listed.
NCT00899197 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00899197 about?
NCT00899197 is a clinical study titled "Tamoxifen Resistance in Women With Stage I, Stage II, Stage IIIA, or Stage IIIB Breast Cancer". RATIONALE: Studying samples of blood from patients with breast cancer in the laboratory may help doctors identify and learn more about biomarkers related to tamoxifen resistance. PURPOSE: This laboratory study is looking at tamoxifen resistance in women with stage I, stage II, stage IIIA, or stage ...
What is the current status of trial NCT00899197?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2007-05. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00899197?
The interventions under investigation include: gene expression analysis (GENETIC), protein expression analysis (GENETIC), laboratory biomarker analysis (OTHER), immunoenzyme technique (OTHER), tamoxifen citrate (DRUG).
Who is sponsoring clinical trial NCT00899197?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.